In 2022, two updated classification systems for lymphoid neoplasms were published by the World Health Organization (WHO Classification of Haematolymphoid Tumours, 5th edition, referred to hereafter as WHO-HAEM5) and the International Consensus Conference (ICC) (Alaggio et al. in Leukemia 36(7):1720–1748, 2022; Campo et al. in Blood 140(11):1229–1253, 2022). Both classifications were conceived by both pathologists and clinicians with expertise in the field. The reasons for this have been reviewed previously (Arber et al. in Virchows Arch 482(1):1–9, 2023; Cree in Leukemia 36(7):1701–1702, 2022, Leukemia 36(11):2750, 2022). Given that both groups were using data-driven processes and consensus and used the revised 4th edition of the WHO Classification of Haematolymphoid Tumours (WHO-HAEM4R) as a starting point, it is not entirely surprising that the resulting classifications are quite similar. However, they are not identical and reflect preferences or approaches for certain unsettled areas as well as preferred terminology. In this review, we will compare nomenclature of the WHO-HAEM5 and ICC classifications, focusing on lymphoid neoplasms and lymphoproliferative disorders (LPDs).

中文翻译：

---

成熟 B、T 和 NK 细胞、浆细胞和组织细胞/树突状细胞肿瘤：根据世界卫生组织和国际共识分类进行分类


2022 年，世界卫生组织（WHO 血淋巴肿瘤分类，第 5 版，以下简称 WHO-HAEM5）和国际共识会议 （ICC）（Alaggio 等人在《白血病》中发布 36（7）：1720–1748,2022 年;Campo 等人在血液 140（11）：1229–1253,2022 年）。这两种分类都是由具有该领域专业知识的病理学家和临床医生构思的。其原因之前已经回顾过（Arber 等人在 Virchows Arch 482（1）：1-9,2023 年;Cree in Leukemia 36（7）：1701–1702， 2022， 白血病 36（11）：2750， 2022）。鉴于两个小组都使用数据驱动的过程和共识，并使用修订后的 WHO 血淋巴瘤分类第 4 版 （WHO-HAEM4R） 作为起点，因此得出的分类非常相似也就不足为奇了。但是，它们并不相同，反映了对某些未解决领域的偏好或方法以及首选术语。在本综述中，我们将比较 WHO-HAEM5 和 ICC 分类的命名法，重点关注淋巴肿瘤和淋巴增生性疾病 （LPD）。